💨 Abstract

Spyre Therapeutics (SYRE) reported a first-quarter loss of $44.8 million, or 74 cents per share, exceeding Wall Street's expectation of a 76-cent loss per share, according to Zacks Investment Research.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖

Powered by MessengerX.io